Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Roche withdraws Tecentriq combo application in first-line renal cell carcinoma

pharmafileNovember 20, 2018

Tag: Bevacizumab , PD-L1 , RCC

PharmaSources Customer Service